Naturally Fluorescent Molecules May Serve' as Cancer Biomarker

April 2009
Bioworld Week;4/27/2009, Vol. 17 Issue 17, p1
The article reports on the findings of the Penn State University researchers on the potential of excess amounts of naturally fluorescent molecule as a biomarker for cancer. It cites nicotinamide adenine dinucleotide (NADH) as the key coenzyme found in the inner membrane of a cell's power plant or mitochondria. Meanwhile, Ahmed Heikal, associate professor of bioengineering at Penn State, relates the function of the NADH as well as NADH's association with cancer and other serious health problems.


Related Articles

  • Naturally Fluorescent Molecules May Serve as Cancer Biomarker. Pedersen, Amanda // BioWorld Today;4/20/2009, Vol. 20 Issue 74, p1 

    The article reveals that excess amounts of the fluorescent molecule could serve as a biomarker for cancer, according to researchers at Penn State University. Nicotinamide adenine dinucleotide (NADH) is a key coenzyme found in the inner membrane of a cell's power plant. Associate professor Ahmed...

  • Test may separate benign from aggressive prostate cancer. BREINDL, ANETTE // Medical Device Daily;2/13/2009, Vol. 13 Issue 29, p1 

    The article reports on the potential role of sarcosine, a type of amino acid, in separating aggressive from indolent cancers. It was identified by a team from the University of Michigan, Ann Arbor, Pennsylvania State University, State College and Metabolon of Durham, North Carolina. They note...

  • Sequence variations of mitochondrial DNA D-loop region are highly frequent events in familial breast cancer. Yu, Man; Shi, Yurong; Zhang, Fei; Zhou, Yunli; Yang, Yi; Wei, Xiyin; Zhang, Lin; Niu, Ruifang // Journal of Biomedical Science;Jul2008, Vol. 15 Issue 4, p535 

    Mitochondrial DNA (mtDNA) is known for its high frequencies of polymorphisms and mutations. The non-coding displacement (D)-loop, especially a mononucleotide repeat (poly-C) between 303 and 315 nucleotides (D310), has been recently identified as a frequent hotspot of mutations in human...

  • Egypt.  // MEED: Middle East Economic Digest;3/5/1999, Vol. 43 Issue 9, p18 

    Reports that researcher Ahmed Heikal discussed issues affecting Egypt's capital market at the MEEDMONEY Conference in London, England on February 23-24, 1999. Evolutions and changes in the market noted by Heikal.

  • Naturally fluorescent molecules may serve as cancer biomarker. PEDERSEN, AMANDA // Diagnostics & Imaging Week;4/16/2009, Vol. 12 Issue 15, p1 

    The article reports that excess amounts of a naturally fluorescent molecule, nicotinamide adenine dinucleotide (NADH), might serve as a natural biomarker for cancer. According to researchers from Pennsylvania State University at University Park, the molecule could be the key to differentiating...

  • Use of NQO1 status as a selective biomarker for oesophageal squamous cell carcinomas with greater sensitivity to 17-AAG. Hadley, Katie E.; Hendricks, Denver T. // BMC Cancer;2014, Vol. 14 Issue 1, p1 

    Background Oesophageal squamous cell carcinoma (OSCC) is a major health burden in Sub-Saharan Africa, and novel chemotherapies are urgently required to combat this disease. The heat shock protein 90 (HSP90) inhibitor 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) has previously been proposed...

  • Reduced Nicotinamide Adenine Dinucleotide (NADH) Fluorescence for the Detection of Cell Death. Hsing-Wen Wang; Yau-Huei Wei; Han-Wen Guo // Anti-Cancer Agents in Medicinal Chemistry;2009, Vol. 9 Issue 9, p1012 

    NADH/FAD fluorescence spectroscopy/imaging is an extremely useful tool to probe cellular metabolism and has been applied in the clinic such as early cancer detection. Recently, the potential of using NADH/FAD fluorescence as a biomarker to detect cell death has been investigated for development...

  • Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. Danson, S. J.; Johnson, P.; Ward, T. H.; Dawson, M.; Denneny, O.; Dickinson, G.; Aarons, L.; Watson, A.; Jowle, D.; Cummings, J.; Robson, L.; Halbert, G.; Dive, C.; Ranson, M. // Annals of Oncology;Jul2011, Vol. 22 Issue 7, p1653 

    Background: This trial describes a first-in-man evaluation of RH1, a novel bioreductive drug activated by DT-diaphorase (DTD), an enzyme overexpressed in many tumours.Patients and methods: A dose-escalation phase I trial of RH1 was carried out. The primary objective was to establish the maximum...

  • Breast Cancer Redox Heterogeneity Detectable with Chemical Exchange Saturation Transfer (CEST) MRI. Cai, Kejia; Xu, He; Singh, Anup; Moon, Lily; Haris, Mohammad; Reddy, Ravinder; Li, Lin // Molecular Imaging & Biology;Oct2014, Vol. 16 Issue 5, p670 

    Purpose: Tissue redox state is an important mediator of various biological processes in health and diseases such as cancer. Previously, we discovered that the mitochondrial redox state of ex vivo tissues detected by redox scanning (an optical imaging method) revealed interesting tumor redox...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics